HLA-B*58:01与美国别嘌醇诱导的严重皮肤不良反应风险
该遗传关联研究纳入2015至2024年间16例经专科裁定的别嘌醇诱导SJS/TEN或DRESS患者,与160例别嘌醇耐受对照按10:1匹配比较。发现HLA-B*58:01(OR 28.0,95%CI 8.6-100.6)和HLA-A*34:02(OR 20.6,95%CI 3.3-131.1)独立增加SCAR风险,但HLA-B*58:01在超过三分之一患者中缺失,为不完全风险指标。
要点
- HLA-B*58:01与别嘌醇诱导SCAR风险显著相关(OR 28.0)。
- HLA-A*34:02为第二个独立遗传风险因素(OR 20.6)。
- HLA-B*58:01在超过三分之一SCAR患者中缺失,预测价值不完全。
核心结论
- HLA-B*58:01与美国别嘌醇诱导SCAR风险相关,但在超过三分之一患者中缺失,为不完全风险指标。
- HLA-A*34:02是美国别嘌醇诱导SCAR队列中第二个独立遗传风险因素。
研究设计与样本
- 遗传关联研究,纳入2015年1月1日至2024年12月31日经专科裁定的别嘌醇诱导SJS/TEN或DRESS患者16例。
- 对照为Vanderbilt大学医学中心生物库中别嘌醇耐受对照160例(10:1匹配)及人群对照,匹配年龄、性别和自我认定的种族。
- 采用条件logistic回归分析HLA I类和II类等位基因与SCAR的关联,Bonferroni校正P<.05。
主要发现
- HLA-B*58:01与别嘌醇诱导SCAR风险增加独立相关(OR 28.0,95%CI 8.6-100.6)。
- HLA-A*34:02与别嘌醇诱导SCAR风险增加独立相关(OR 20.6,95%CI 3.3-131.1)。
- 未发现达到Bonferroni校正P<.05显著性水平的HLA II类等位基因。
- HLA-B*58:01在超过三分之一的患者队列中缺失。
关键数值与推荐
- HLA-B*58:01携带者别嘌醇诱导SCAR风险OR 28.0(95%CI 8.6-100.6)。
- HLA-A*34:02携带者别嘌醇诱导SCAR风险OR 20.6(95%CI 3.3-131.1)。
- HLA II类等位基因未达Bonferroni校正P<.05显著性水平。
临床怎么用
- HLA-B*58:01可作为别嘌醇诱导SCAR的风险筛查指标,但阴性不能完全排除风险。
- HLA-A*34:02可作为美国人群别嘌醇诱导SCAR的额外遗传风险标志物。
- 需开展基于人群的研究以重复已知关联并发现新HLA关联,用于筛查、风险分层和诊断。
局限性
- 样本量较小(16例SCAR患者)。
- 研究基于美国单一中心生物库人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Carriage of HLA-B*58:01 has been shown to be associated with allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) in many populations globally; however, there is a critical need to investigate whether this is generalizable to populations of mixed ancestry, such as those in the US. OBJECTIVE: To assess the association of human leukocyte antigen (HLA) class I and II in a cohort of US patients who received a diagnosis of allopurinol-induced SJS/TEN or DRESS compared with allopurinol-tolerant and population control participants. DESIGN, SETTING, AND PARTICIPANTS: This genetic association study included consenting individuals who had specialist-adjudicated allopurinol-induced SJS/TEN or DRESS (collectively allopurinol-induced severe cutaneous adverse reactions [SCARs]) between January 1, 2015, and December 31, 2024. HLA carriage in these individuals was compared with allopurinol-tolerant and population control participants identified through the Vanderbilt University Medical Center biobank, which includes 94 489 individuals with imputed HLA class I and II typing from genotyping array data. Data were analyzed from January 2025 to August 2025. MAIN OUTCOMES AND MEASURES: The main outcome measure was the association of HLA class I and II alleles with allopurinol-induced SCARs. HLA class I and II conditional logistic regression case-control analyses were performed between patients with allopurinol-induced SCARs and both population control and allopurinol-tolerant control participants matched on age, sex, and self-identified race. Odds ratios (ORs) and 95% CIs were reported, with Bonferroni-corrected P < .05. RESULTS: This genetic association study used conditional logistic regression analyses and included 16 patients with allopurinol-induced SCAR (mean [SD] age, 61.1 [12.6] years; 9 female patients [56.25%] and 7 male patients [43.75%]) and 160 allopurinol-tolerant control participants matched 10:1. Two HLA class I alleles were found to be independently associated with increased risk of allopurinol-induced SCAR: HLA-B*58:01 (OR, 28.0 [95% CI, 8.6-100.6]) and HLA-A*34:02 (OR, 20.6 [95% CI, 3.3-131.1]). No HLA class II alleles meeting the Bonferroni-corrected P < .05 level of significance were identified. CONCLUSIONS AND RELEVANCE: These findings suggest that although HLA-B*58:01 was found to be associated with allopurinol-induced SCARs, generalizing findings from previous studies, the allele was absent in more than one-third of the patient cohort and is therefore an incomplete indicator of risk. Importantly, in the US allopurinol-induced SCAR cohort, HLA-A*34:02 was found to be a second independent genetic risk factor for allopurinol-induced SCARs. These findings underscore the need to conduct population-based studies that both reproduce known and uncover novel HLA associations to reduce harm through contributions to screening, risk stratification, and diagnosis.
引用
- Campbell CN, Krantz MS, Yu A, et al. HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US. JAMA Dermatol. 2025. PMID: 41160012. doi:10.1001/jamadermatol.2025.4240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。